TerminatedPhase 1NCT03759184

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

Studying Bronchiolitis obliterans

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Kevin C Conlon, M.D., MFT
National Cancer Institute (NCI)
Intervention
rhIL-15(drug)
Enrollment
1 enrolled
Eligibility
18 years · All sexes
Timeline
20192021

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03759184 on ClinicalTrials.gov

Other trials for Bronchiolitis obliterans

Additional recruiting or active studies for the same condition.

See all trials for Bronchiolitis obliterans

← Back to all trials